Khurram Jamil Buys Shares of GALT
Khurram Jamil, GALT's Chief Medical Officer, purchased 7,557 shares on June 23, 2026.
Key Points
- Khurram Jamil, Chief Medical Officer of GALT, purchased 7,557 shares at $1.23 per share, amounting to $9,295.11 on June 23, 2026.
- GALT shares traded at $4.14 on Friday, with institutional investors like Vanguard opening a new position with 1,966,542 shares.
- Analyst HC Wainwright & Co. reiterated a 'buy' rating for GALT with a price target of $11 on June 23, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Khurram Jamil, Chief Medical Officer at GALT, recently bought 7,557 shares of the company at an average price of $1.23, totaling $9,295.11. This transaction took place on June 23, 2026, and was not part of a pre-arranged trading plan.
Other Institutional Activity in GALT
Vanguard Capital Management LLC opened a new position in GALT, acquiring 1,966,542 shares valued at approximately $5,486,652. Meanwhile, Marshall Wace, LLP increased its holdings by 617,778 shares, bringing its total to 1,219,912 shares worth about $3,403,554, marking a 102.6% increase. Osaic Holdings, Inc. added 32,080 shares, ending with 1,122,670 shares valued at $3,132,240, a 2.9% increase. BlackRock, Inc. slightly boosted its stake by 2,679 shares to hold 799,237 shares, valued at around $2,229,871. Millennium Management LLC significantly increased its position by 562,926 shares, now holding 798,434 shares worth $2,227,631, reflecting a 239% increase.
Galectin Therapeutics Inc. Stock Up 3.0%
Shares of GALT traded near $4.14 on Friday. The stock has seen institutional interest with several funds increasing their stakes recently. While exact market cap and P/E information isn't available, the stock's recent price activity and analyst attention suggest ongoing interest.
$GALT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 23, 2026, HC Wainwright & Co. reiterated its 'buy' rating on GALT, maintaining a price target of $11. This firm has consistently supported GALT with a strong buy recommendation, reflecting confidence in the company's future prospects.
Insider Buying and Selling at Galectin Therapeutics Inc.
Khurram Jamil, Chief Medical Officer, engaged in multiple transactions. On June 23, 2026, he purchased 7,557 shares at $1.23 per share. Earlier, on May 26, 2026, he made another purchase of 568 shares at the same price. These transactions were not executed under a pre-planned trading agreement.
About GALT
GALT is a company involved in the biotechnology sector, focusing on developing therapies for fibrotic diseases. The company is headquartered in the United States and is actively engaged in research and development to advance its clinical programs.
Bottom Line
Khurram Jamil's recent purchase of GALT shares indicates his confidence in the company's direction. Institutional activity shows a mix of new entries and increased positions by major funds, suggesting broader interest. Analyst support remains strong, with HC Wainwright & Co. reiterating a 'buy' rating, pointing to optimism about GALT's future performance.
Get Galectin Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $GALT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.